Published in May 2015
An analysis from the SHIFT trial assessed the impact of multiple comorbidities on outcomes and the potential impact on the benefits of ivabradine in heart failure patients. Multimorbidity was associated with a higher risk of outcomes but, whatever the number of comorbidities, did not interfere with the effects of ivabradine in reducing the primary end point of cardiovascular death or hospitalization for heart failure or in reducing other heart failure-related outcomes.
1. Böhm M et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. Eur J Heart Fail. 2015:17(Supplement 1):266. Abstract 1283.